FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Wong Vivien		 2. Issuer Name and Ticker or Trading Symbol

PROGENICS PHARMACEUTICALS INC [ PGNX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, Development
(Last)          (First)          (Middle)

ONE WORLD TRADE CENTER, 47TH FLOOR, SUITE J		 3. Date of Earliest Transaction (MM/DD/YYYY)

6/19/2020
(Street)

NEW YORK, NY 10007
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 6/19/2020  D  4121 D (1)0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $5.35 6/19/2020  D     6000   (2)6/30/2020 Common Stock 6000  (3)0 D  
Stock Option (Right to Buy) $4.83 6/19/2020  D     25000   (2)10/31/2020 Common Stock 25000  (3)0 D  
Stock Option (Right to Buy) $7.40 6/19/2020  D     60000   (2)6/30/2021 Common Stock 60000  (3)0 D  
Stock Option (Right to Buy) $9.81 6/19/2020  D     40000   (2)2/28/2022 Common Stock 40000  (3)0 D  
Stock Option (Right to Buy) $5.03 6/19/2020  D     48000   (2)4/3/2023 Common Stock 48000  (3)0 D  
Stock Option (Right to Buy) $4.70 6/19/2020  D     52800   (2)3/2/2024 Common Stock 52800  (3)0 D  
Stock Option (Right to Buy) $4.70 6/19/2020  D     75000   (2)3/2/2024 Common Stock 75000  (3)0 D  
Stock Option (Right to Buy) $6.65 6/19/2020  D     66000   (2)3/1/2025 Common Stock 66000  (3)0 D  
Stock Option (Right to Buy) $4.52 6/19/2020  D     82500   (2)2/28/2026 Common Stock 82500  (3)0 D  
Stock Option (Right to Buy) $11.32 6/19/2020  D     82500   (2)2/28/2027 Common Stock 82500  (3)0 D  
Stock Option (Right to Buy) $6.62 6/19/2020  D     94875   (4)2/29/2028 Common Stock 94875  (3)0 D  
Stock Option (Right to Buy) $4.52 6/19/2020  D     90750   (5)3/1/2029 Common Stock 90750  (3)0 D  
Stock Option (Right to Buy) $4.77 6/19/2020  D     82214   (6)3/2/2030 Common Stock 82214  (3)0 D  
Explanation of Responses:
(1) On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. Pursuant to the Merger Agreement, each share of Progenics common stock was cancelled and converted into the right to receive (i) 0.31 of a share of Lantheus common stock (with such fraction of a Lantheus share having a market value of $4.60 on the effective date of the Merger) and (ii) one contingent value right (a "CVR") issued by Lantheus subject to and in accordance with the Contingent Value Rights Agreement, dated June 19, 2020, between Lantheus and Computershare Trust Company, N.A.
(2) Each of these options is fully vested and exercisable.
(3) At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the current vesting and other terms of the option continue in effect.
(4) This option is scheduled to vest in annual installments over the three-year period commencing March 1, 2018.
(5) This option is scheduled to vest in annual installments over the three-year period commencing March 1, 2019.
(6) This option is scheduled to vest in annual installments over the three-year period commencing March 2, 2020.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Wong Vivien
ONE WORLD TRADE CENTER
47TH FLOOR, SUITE J
NEW YORK, NY 10007

EVP, Development
Signatures
/s/ Vivien Wong6/23/2020
**Signature of Reporting PersonDate
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Progenics Pharmaceuticals Charts.
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Progenics Pharmaceuticals Charts.